Human papillomavirus vaccine - AnGes

Drug Profile

Human papillomavirus vaccine - AnGes

Alternative Names: BLS-ILB-E710c; CIN therapeutic vaccine - AnGes; GLBL101c; HPV vaccine + lactobacillus carrier - AnGes/Bioleaders/GenoLac/Morishita Jintan/University of Tokyo; Oral HPV vaccine - AnGes/Bioleaders/GenoLac/Morishita Jintan/University of Tokyo

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioleaders Corporation
  • Developer AnGes MG; Bioleaders Corporation; Morishita Jintan; University of Tokyo
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections

Most Recent Events

  • 30 Aug 2017 Phase-II clinical trials in Cervical intraepithelial neoplasia in South Korea (PO) (NCT03274206)
  • 16 Jun 2016 Phase II development is ongoing in Japan (UMIN000012229),
  • 01 Apr 2016 BioLeaders Corporation completes a phase I/II trial in Cervical intraepithelial neoplasia in South Korea (PO) (NCT02195089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top